Maynard Um
-
-
-
-
-
-
-
Raymond James Reiterates Strong Buy Rating on Ardelyx, Inc (ARDX)
-
-
-
-
-
-
-
Ardelyx reports $378 million in 2025 revenue, projects growth
-
-
-
-
-
-
-
Ardelyx presents IBSRELA data at gastroenterology meeting
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Ardelyx, Inc (ARDX)
-
-
-
-
-
-
-
Ardelyx (ARDX) to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings
-
-
-
-
-
-
-
Ardelyx (ARDX) Tops Q4 EPS by 1c
-
-
-
-
-
-
-
Ardelyx (ARDX) Reports Additional Data Supporting First-In-Class XPHOZAH
-
401,484 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

